Pharmatest Impress Bayer with High Quality Work for FDA Approved Cancer Drug Xofigo

Press Release – Pharmatest Services Ltd
Pharmatest Impress Bayer with High Quality Work for FDA Approved Cancer Drug Xofigo

Pharmatest Logo

Contact Supplier: Pharmatest Services Ltd
Supplier Press Release: Pharmatest Impress Bayer with High Quality Work for FDA Approved Cancer Drug Xofigo
Address: Itäinen Pitkäkatu 4 C, 5th floor, 20520 Turku, Finland
Tel: +358 2 278 4700
Fax: +358 2 278 4710
Website: www.pharmatest.com

JULY 02, 2013

Pharmatest Impress Bayer with High Quality Work for FDA Approved Cancer Drug Xofigo

Bayer the German drug maker praises Pharmatest Services Ltd for the high quality of work it has provided during the collaboration for Bayer’s cancer drug Xofigo that has recently been approved by the US Food and Drug Agency (FDA).

Pharmatest has been Bayer’s supplier of choice since 2010 and have successfully collaborated on several projects. Most recently they have worked together on a number of studies related to Bayer’s cancer drug Xofigo (radium-223 dichloride). Pharmatest has established a productive and beneficial relationship with Bayer over the years providing knowledge and expertise in clinically predictive preclinical efficacy services in the therapeutic areas of oncology and skeletal diseases.

Dr. Karl Ziegelbauer, Senior Vice President of Global Drug Discovery, TRG Oncology/GT at Bayer said “Bayer has worked for several years with Pharmatest and we are very impressed about the high quality of the work they have done for us.”

The recently FDA approved drug is used for treating bone metastases in castration-resistant prostate cancer. Cancer cells can spread from the prostate to other parts of the body particularly the bones. Nearly 90% of patients with metastatic prostate cancer show signs of bone metastases.

The results have been published in the Journal of the National Cancer Institute (impact factor 13.76) in a paper that demonstrates efficacy of radium-223 dichloride also for bone metastases in breast cancer.

“This new publication will be important for Pharmatest in convincing potential new customers about the high quality and clinical predictivity of the services that we offer. I want to thank Bayer for the trust and confidence in Pharmatest being able to perform these very important studies for them” commented Pharmatest’s CEO Jussi Halleen.

About Pharmatest Services Ltd
Pharmatest Services Ltd is a contract research organisation specialised in clinically predictive preclinical efficacy services in the therapeutic areas of oncology and skeletal diseases.

Head quartered in Turku, Finland, its preclinical research unit offers modern research facilities including fully equipped laboratories and barrier-type animal facilities.

Key to Pharmatest’s specialist services is its desire to improve the speed and efficiency of nonclinical drug development and reduce the amount of drug candidates failing in clinical trials. Pharmatest has a proven ability to reduce costs and notably increase the speed of drug development by processing outsourced preclinical efficacy testing with the maximum efficiency. Working with Pharmatest gives you an on-demand access to latest translational tools for lead validation and proof-of-concept studies in oncology and skeletal diseases.

Pharmatest helps clients to establish the proof-of-efficacy of your cancer drug candidates with cell culture assays, organotypic 3D models, orthotopic animal models, and disseminated cancer models. Its models of skeletal diseases include bone cell culture assays and animal models of osteoporosis and osteoarthritis that can also be used for bone safety testing.

Pharmatest has supported close to one hundred clients – from both the pharmaceutical and biotechnology industries – around the world in their research to develop new therapeutics against cancer and skeletal diseases. It has also assisted many nutraceutical companies in the development of new phytopharmaceutical products.

For more information or to discuss Pharmatest collaborating with Bayer please contact us directly.

Comments are closed.